---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-067544"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2024-06-03T23:59:59+00:00"
generated_at: "2026-06-01T06:45:06.660343+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Ocular Therapeutix cuts 13% of workforce, 37 jobs, to prioritize AXPAXLI

## Summary
- Board approved reduction in force of 37 employees (~13% of workforce), mainly in R&D and technical operations.
- Action taken to focus resources on AXPAXLI (axitinib intravitreal implant) for wet AMD clinical development.
- Expects total restructuring costs of $1.0 to $2.0 million for severance and related costs in Q2/Q3 2024.
- Reduction expected to be substantially completed in Q2 2024.

## SEC filing metadata
- accession: 0001104659-24-067544
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2024-06-03T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.05
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465924067544/0001104659-24-067544-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465924067544/tm2416236d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-067544
- JSON: https://secwatch.observer/filing/0001104659-24-067544.json
- Plain text: https://secwatch.observer/filing/0001104659-24-067544.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.